Egetis' Emcitate NDA for MCT8 Deficiency Advances Toward September 28, 2026 FDA Decision
核心洞察
Egetis Therapeutics (搜索)' New Drug Application for Emcitate (tiratricol) in MCT8 deficiency (搜索) is under FDA Priority Review, with a PDUFA target action date of September 28, 2026.
The FDA has confirmed it expects to complete its review by the PDUFA date and does not plan to hold an advisory committee meeting.
Emcitate sales in Europe reached MSEK 17.4 in Q2 2026, a 23% increase at constant exchange rates compared with Q2 2025.
Egetis Therapeutics (搜索) AB (publ) (NASDAQ Stockholm: EGTX) is advancing toward a pivotal regulatory milestone, with the U.S. Food and Drug Administration (FDA) progressing its review of the New Drug Application (NDA) for Emcitate (tiratricol) in the treatment of monocarboxylate transporter 8 (MCT8 (搜索)) deficiency. The application has been granted Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 28, 2026.
The most significant event during the first half of 2026 was the acceptance, and the grant of priority review, of the NDA by the FDA. According to CEO Nicklas Westerholm, "Thus far, the review has been constructive, and the mid-cycle as well as the late-cycle meetings have been held with the agency, which has confirmed that FDA expects to finish its review by the PDUFA date of September 28, 2026 and does not plan to hold an advisory committee meeting."
MCT8 Deficiency and the Emcitate Clinical Program
MCT8 deficiency (搜索), also known as Allan-Herndon-Dudley syndrome (搜索), is a rare, devastating, and life-shortening genetic disorder caused by mutations in the gene coding for MCT8 (搜索). The condition is characterized by disrupted thyroid hormone signaling, and there has historically been no available treatment.
Emcitate (tiratricol) is Egetis' lead drug candidate, developed for the treatment of patients with MCT8 deficiency (搜索). In February 2025, the European Commission approved Emcitate as the first and only treatment for MCT8 deficiency in the EU, and Egetis initiated its launch in Germany on May 1, 2025.
The NDA for Emcitate is based on clinical data from Triac Trial I, Triac Trial II, ReTRIACt, the EMC Cohort Study, the EMC Survival Study, and the US Expanded Access Program. Tiratricol holds Orphan Drug Designation for MCT8 deficiency (搜索) and resistance to thyroid hormone beta (搜索) (RTH-beta) in both the US and the EU. It has also been granted Breakthrough Therapy Designation and Rare Pediatric Disease Designation (RPDD) by the FDA.
Expanded Access Program and U.S. Launch Preparations
At the FDA's request, Egetis has implemented an Expanded Access Program (EAP) in the U.S. Currently, 17 hospitals are included and approximately 60 patients are receiving tiratricol in the EAP. The program allows physicians to access tiratricol for patients not eligible for clinical trials prior to marketing approval, as well as for continued treatment of patients who completed the ReTRIACt and Triac Trial II studies.
Egetis has accelerated its preparatory launch activities in the U.S. and the build-out of its commercial and medical affairs infrastructure. During the period, the company contracted a specialty pharmacy and a distributor to assist in providing Emcitate to patients with MCT8 deficiency (搜索) after approval. The company also announced a national re-airing of a "Behind the Mystery" episode on Lifetime spotlighting MCT8 deficiency, featured on The Balancing Act, broadcast nationally in the U.S. on the Lifetime Network.
Priority Review Voucher Value
As Emcitate has been granted Rare Pediatric Disease Designation by the FDA, Egetis is eligible to receive a Priority Review Voucher (PRV) upon potential approval. PRVs are transferable and can be sold to other companies, creating an active secondary market. PRVs sold in 2026 have fetched USD 180–220 million each, with the highest price of USD 220 million announced by the buyer, BMS, on July 30, 2026. Egetis is entitled to 50 percent of net proceeds from any Emcitate-related PRV sale, with the remainder paid as earnout to Rare Thyroid Therapeutics International AB sellers following the acquisition of Emcitate in 2020.
U.S. Patent Grant
On May 5, 2026, the United States Patent and Trademark Office (USPTO) granted Patent No. US 12611383B1 for Egetis' patent application No. 19/261,360, entitled "Pharmaceutical Compositions for Treating MCT8 Deficiency (搜索)." This is the first patent granted for Emcitate and provides protection for a novel composition containing tiratricol as the active ingredient, designed to correct the disrupted thyroid hormone signaling characteristic of MCT8 deficiency. The claims cover, among other things, a method of treating MCT8 deficiency with the claimed pharmaceutical composition encompassing tiratricol, dosing regimens, and tiratricol compositions with specific excipients. Egetis expects the granted patent will be Orange Book-listable, with a patent expiration date in 2045.
European Commercialization and Financial Position
Revenue from Emcitate sales in Europe during the second quarter of 2026 was MSEK 17.4, a 23% increase at constant exchange rates compared with Q2 2025. The Emcitate price negotiations within the German reimbursement process (AMNOG) concluded in Q2 2026 and are valid from August 1. In Spain, Egetis has recently submitted a national pricing and reimbursement dossier for Emcitate, while in Italy and France the company plans to strengthen its value dossiers with survival data once published in a peer-reviewed journal by Erasmus Medical Center.
For the January–June period, revenue was MSEK 30.7 (27.1), a 13% increase at constant exchange rates. Cash at the end of the quarter amounted to MSEK 378.4 (202.6). On April 21, 2026, Egetis successfully carried out an oversubscribed directed share issue amounting to MSEK 350 (approximately MUSD 38) gross at SEK 5.25 per share.
Partner Progress and Next Indication
Egetis' Japanese partner Fujimoto Pharmaceuticals, which holds an exclusive license for the development and commercialization of Emcitate for MCT8 deficiency (搜索) in Japan, continues to prepare the Japanese NDA submission dossier, with submission expected in the beginning of 2027. Distribution partners Er-Kim (Turkey, Central, Eastern, and Southeastern Europe) and Taiba rare (Gulf region) are actively identifying patients in their respective territories. In Australia, Egetis recently signed a supply agreement with Orspec Pharma to reach more patients in Australia and New Zealand.
Looking ahead, Egetis is working to finalize the development plan for Emcitate in RTH-beta, convening a scientific advisory board and preparing for regulatory interactions to discuss the proposed clinical development plan. MCT8 deficiency (搜索) and RTH-beta are two distinct indications, with no overlap in patient populations.